Generic Atacand Availability
ATACAND (candesartan cilexetil - tablet;oral)
Approval date: June 4, 1998
Strength(s): 4MG [AB], 8MG [AB], 16MG [AB], 32MG [RLD] [AB]
Has a generic version of Atacand been approved?
A generic version of Atacand has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Atacand and have been approved by the FDA:
Approval date: May 3, 2013
Strength(s): 4MG [AB], 8MG [AB], 16MG [AB], 32MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Atacand. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-c arboxylate and compositions and methods of pharmaceutical use thereof
Issued: March 23, 1993
Inventor(s): Naka; Takehiko & Nishikawa; Kohei & Kato; Takeshi
Assignee(s): Takeda Chemical Industries, Ltd.
1-(Cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-car boxylate or a pharmaceutically acceptable salt thereof has potent angiotensin II antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.Patent expiration dates:
- December 4, 2012✓
- December 4, 2012
Pharmaceutical compositions for oral use and method of preparing them
Issued: July 9, 1996
Inventor(s): Makino; Tadashi & Mizukami; Yashio & Kikuta; Jun-ichi
Assignee(s): Takeda Chemical Industries, Ltd.
A pharmaceutical composition for oral use comprising an effective amount of a compound of the formula (I) having antagonistic action to angiotensin II ##STR1## (wherein the ring W is an optionally substituted N-containing heterocyclic residue; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; and n is an integer of 1 or 2) and an oily substance having a lower melting point, and a method for preparing a pharmaceutical composition for oral use comprising an effective amount of a compound of the formula (I) and an oily substance having a lower melting point, which comprises admixing the compound of the formula (I) with an oily substance having a lower melting point and then subjecting the mixture to molding.Patent expiration dates:
- July 9, 2013✓
- January 9, 2014✓
- July 9, 2013
- Atacand Consumer Information (Drugs.com)
- Atacand Consumer Information (Wolters Kluwer)
- Atacand Consumer Information (Cerner Multum)
- Atacand Advanced Consumer Information (Micromedex)
- Atacand AHFS DI Monographs (ASHP)
- Candesartan Consumer Information (Wolters Kluwer)
- Candesartan Consumer Information (Cerner Multum)
- Candesartan Advanced Consumer Information (Micromedex)
- Candesartan cilexetil Advanced Consumer Information (Micromedex)
- Candesartan Cilexetil AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
|AB||Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.|